Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents

Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents

Locametz<sup>®</sup>/Illuccix<sup>®</sup>/Gozellix<sup>TM</sup> (Novartis AG (Basel, Switzerland) and Telix Pharmaceuticals, Ltd. (Melbourne, Australia), all three [<sup>68</sup>Ga]Ga-PSMA-11), Pylarify<sup>®</sup>/Pylclari<sup>®</...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ute Hennrich, Laurène Wagner, Harun Taş, Luciana Kovacs, Martina Benešová-Schäfer
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Pharmaceuticals
Subjects:	prostate cancer PSMA PET diagnostics fluorine-18 gallium-68 FDA approval
Online Access:	https://www.mdpi.com/1424-8247/18/6/906
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparing the Diagnostic Performance of [18F]PSMA‐1007 With [68Ga]Ga‐PSMA‐11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer
by: Negar Abdi, et al.
Published: (2025-03-01)

Development of a homotrimeric PSMA radioligand based on the NOTI chelating platform
by: Sebastian Martin, et al.
Published: (2024-12-01)

FDG PET/CT AND PSMA PET/CT IN MUSCULOSKELETAL SOFT TISSUE SARCOMAS
by: Ellen Nogueira Lima, et al.
Published: (2025-05-01)

Unexpected discovery of hepatic cancer via 68Ga-PSMA PET/CT in the staging of prostate cancer
by: Radu Alexa, et al.
Published: (2025-06-01)

Head-to-head comparison of 68Ga-PSMA-11 and 18F-FDG in delayed PET/CT imaging in prostate cancer diagnosis
by: Biyao Hu, et al.
Published: (2025-04-01)

THE IMPACT OF 68GA-PSMA PET/CT ON THERAPY MANAGEMENT OF HIGH RISK PROSTATE CANCER
by: Duygu Has Şimşek, et al.
Published: (2021-01-01)

COMPARISON BETWEEN 18F-PSMA AND 18F-FDG RADIOTRACERS FOR PET/CT IN THE EVALUATION OF PATIENTS WITH METASTATIC MELANOMA
by: Thiago Soare Rocha Alves, et al.
Published: (2025-05-01)

Preliminary clinical study of p-iodo benzoyl moiety-modified PSMA inhibitors and prospective comparison with 68Ga-PSMA-11
by: Jianpeng Cao, et al.
Published: (2025-06-01)

Imply on diagnosis and early prognosis of preoperative [68Ga]Ga-PSMA-11 PET/CT in patients with suspected brain tumours of glial origin
by: K. Pełka, et al.
Published: (2025-01-01)

PET/CT WITH 68GA-FAPI46 FOR THE DETECTION OF PRIMARY AND METASTATIC LESIONS IN PATIENTS WITH DIFFERENT TYPES OF CANCER. INITIAL EXPERIENCE
by: Lilian Yuri Itaya Yamaga, et al.
Published: (2025-05-01)

EVALUATION OF 18F-PSMA PET/CT UPTAKE IN PATIENTS WITH GASTRIC ADENOCARCINOMA: AN EXPLORATORY ANALYSIS
by: Renata Erbert Contriciani, et al.
Published: (2025-05-01)

An Evaluation of the Diagnostic Accuracy of [68Ga]Ga-PSMA-11 vs. [18F]F-PSMA-1007 PET/CT for Lymph Node Staging in Patient Candidates for Radical Prostatectomy and Lymph Node Dissection: A Single Institutional Analysis
by: Paola Arena, et al.
Published: (2025-06-01)

Biochemical failure-free survival of 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer
by: Marco M. E. Vogel, et al.
Published: (2025-01-01)

Comparison of 18F-FDG and 68-PSMA-11 in PET for prostate cancer diagnosis
by: Natalia Fulle, et al.
Published: (2022-12-01)

Development and validation of a visual nomogram for predicting clinically significant prostate cancer in negative mpMRI using 68Ga-PSMA PET/CT
by: Wei Hu, et al.
Published: (2025-07-01)

PET/CT con hallazgo incidental de captación de 18F-PSMA en paciente con COVID-19
by: Jhonatan Gómez-Domínguez, et al.
Published: (2025-01-01)

An Innovative Approach with [<sup>68</sup>Ga]Ga-PSMA PET/CT: The Relationship Between PRIMARY Scores and Clinical and Histopathological Findings
by: Gozde Mutevelizade, et al.
Published: (2025-07-01)

PSMA PET/CT scan reveals incidental meningioma in a prostate cancer patient
by: Venetia A. Florou, et al.
Published: (2025-05-01)

A comparison of routine [68Ga]Ga-PSMA-11 preparation using Locametz and Illuccix kits
by: Ivan E. Wang, et al.
Published: (2024-12-01)

<sup>68</sup>Ga Extemporaneous Preparations in Radiopharmacy
by: Marzia Rizzello, et al.
Published: (2025-06-01)

Furosemide Reduces Radionuclide Activity in the Bladder in <sup>18</sup>F-PSMA-1007-PET/CT: A Single-Center Retrospective Intra-Individual Comparative Study
by: Martin A. Cahenzli, et al.
Published: (2025-07-01)

DUAL-TRACER PET/CT IMAGING IN HEPATOCELLULAR CARCINOMA: COMPARING THE PERFORMANCE OF 18F-FDG AND 18F-PSMA
by: Giulia Picciola Bordoni, et al.
Published: (2025-05-01)

Preclinical evaluation of [68Ga]Ga-AAZTA-FAPI-46: a novel PET tracer for targeting fibroblast activation protein (FAP)
by: Rebecca Rizzo, et al.
Published: (2025-08-01)

Enhancing the diagnostic capacity of [18F]PSMA-1007 PET/MRI in primary prostate cancer staging with artificial intelligence and semi-quantitative DCE: an exploratory study
by: Philip Alexander Glemser, et al.
Published: (2024-11-01)

Indications and Results for Ga-68 PSMA PET/CT in Patients with Biochemical Relapse of Prostate Cancer
by: Ivan Rogić, et al.
Published: (2024-01-01)

Diagnostic value of 18F-PSMA-1007 PET/CT for predicting the pathological grade of prostate cancer
by: Xiao-Bo Niu, et al.
Published: (2024-12-01)

Diagnostic value of dual-tracer PET/CT with [18F]FDG and PSMA ligands in prostate cancer: an updated systematic review
by: Cesare Michele Iacovitti, et al.
Published: (2025-07-01)

Cancers and Benign Processes on 68Ga PSMA PET-CT Imaging Other than Prostate Cancer
by: Pinar Pelin Ozcan, et al.
Published: (2022-06-01)

A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer
by: Matthew J. Roberts, et al.
Published: (2025-07-01)

Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System
by: Zsófia Sára Mikó, et al.
Published: (2024-10-01)

Biphasic contrast-enhanced [18F]PSMA-1007 PET/CT imaging to improve the detection of local relapse of prostate cancer
by: Eduards Mamlins, et al.
Published: (2025-05-01)

AI based automatic measurement of split renal function in [18F]PSMA-1007 PET/CT
by: Kristian Valind, et al.
Published: (2025-06-01)

The impact of patient hydration and forced diuresis on [18F]PSMA-1007 urinary bladder uptake in PET/CT imaging
by: Aleksandr Igorevich Khalimon, et al.
Published: (2025-06-01)

Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) in Initial Staging of Prostate Cancer Patients: The Beginning of a New Era
by: Juan Gómez Rivas, et al.
Published: (2025-05-01)

The impact of preliminary patient hydration on physiological [18F]PSMA-1007 uptake in the urinary bladder on PET/CT
by: T. L. Antonevskaya, et al.
Published: (2024-06-01)

Which PSMA PET/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study
by: Le Ma, et al.
Published: (2025-01-01)

PSMA response evaluation in follow-up PSMA-PET/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer
by: Anna-Lena Zang, et al.
Published: (2025-09-01)

Using radiomics model for predicting extraprostatic extension with PSMA PET/CT studies: a comparative study with the Mehralivand grading system
by: Linjie Bian, et al.
Published: (2025-06-01)

A case of well-differentiated hepatocellular carcinoma identified on gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography
by: Hian Huang, et al.
Published: (2018-04-01)

PSMA-PET-derived distance features as biomarkers for predicting outcomes in primary prostate cancer post-radical prostatectomy
by: Ruohua Chen, et al.
Published: (2025-07-01)